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Available online 10 September 2013The study of healthy human volunteers ascending to high altitude provides a robust model of
the complex physiological interplay that emulates human adaptation to hypoxaemia in clinical
conditions. Nitric oxide (NO) metabolism may play an important role in both adaptation to
high altitude and response to hypoxaemia during critical illness at sea level. Circulating nitrate
and nitrite concentrations can be augmented by dietary supplementation and this is associated
with improved exercise performance and mitochondrial efficiency. We hypothesised that the
administration of a dietary substance (beetroot juice) rich in nitrate would improve oxygen
efficiency during exercise at high altitude by enhancing tissue microcirculatory blood flow and
oxygenation. Furthermore, nitrate supplementation would lead to measurable increases in NO
bioactivity throughout the body.
This methodological manuscript describes the design and conduct of the ‘Xtreme Alps’ expe-
dition, a double-blind randomised controlled trial investigating the effects of dietary nitrate
supplementation on acclimatisation to hypobaric hypoxia at high altitude in healthy human
volunteers. The primary outcomemeasure was the change in oxygen efficiency during exercise
at high altitude between participants allocated to receive nitrate supplementation and those
receiving a placebo. A number of secondary measures were recorded, including exercise
capacity, peripheral and microcirculatory blood flow and tissue oxygenation.
Results from this study will further elucidate the role of NO in adaption to hypoxaemia and
guide clinical trials in critically ill patients. Improved understanding of hypoxaemia in critical
illness may provide new therapeutic avenues for interventions that will improve survival in
critically ill patients.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Keywords:
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Patients commonly experience hypoxaemia (reduced
arterial oxygenation), and none more so than those admitted
to critical care units. Surprisingly little is understood about
the relationship between arterial oxygenation and survival in
the critically ill. Measures to improve patient outcome areD license.
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potential hazards associated with this. It is conceivable that
alternative strategies could benefit those with hypoxaemia in
the setting of established critical illness but the mechanisms
governing possible candidate treatments have yet to be
elucidated [1]. Cellular and animal models have enhanced
our understanding of specific pathways pertinent to hypoxic
adaptation but they fail to provide an integrative physiolog-
ical model for the hypoxaemic critically ill patient.
It has been suggested that the study of healthy human
volunteers ascending to high altitude may provide a valid
model of the complex physiological interplay that permits
human adaptation to hypoxaemia in clinical conditions [2].
Ascent to high altitude is accompanied by a decline in
barometric pressure that causes a reduction in the partial
pressure of oxygen (PO2), termed hypobaric hypoxia. The fall in
inspired partial pressure of oxygen (PIO2) leads to a decline in
arterial oxygenation at high altitude. Levels of hypoxaemia
comparable to those seen in critically ill patients can be
mimicked even at moderate altitude, whilst ascent to over
8000 m above sea level results in levels of hypoxaemia that are
likely to lie at the limit of human acclimatisation capability [3].
Although such an experimental paradigm is not without
limitations [4], it offers a unique insight into human adaptation
to hypoxia that cannot be gained from alternative models.
Our first large-scale study of human volunteers at high
altitude focussed on determining mechanisms of hypoxic
adaptation relevant to the critically ill was carried out in 2007
(Caudwell Xtreme Everest — CXE) [4–6]. Prior to this, many
decades of high altitude research expeditions had sought to
define distinguishing physiological mechanisms in small groups
of selected individuals exposed to hypoxia. In contrast, the CXE
2007 expedition studied a large group of predominantly altitude
naive volunteers who ascended to altitude with an identical
ascent profile. In this way, inter-individual differences in
performance at altitude could be attributed to underlying
responses to the hypoxic challenge. Discrete phenomena could
therefore be studied with the ultimate goal of defining a
phenotype of successful hypoxic adaptation in order to identify
genetic loci and common regulatory/signalling features impor-
tant for adaptation to hypoxia. This approach has already
yielded a number of novel findings thatmerit further evaluation
[1,7–13]. Of specific interest, was the observation that plasma
nitrite and nitrate as well as cyclic guanosine monophosphate
(cGMP), biomarkers of nitric oxide (NO) production, were
elevated on ascent to high altitude and correlated with changes
in microcirculatory blood flow [9]. Along with evidence that
blood nitrite and nitrate are also elevated in native highland
populations [14], this raised important questions relating to
the role of nitrogen oxides in the adaptive response to hypoxia.
The aim of the ‘Xtreme Alps’ study was to explore whether
manipulation of NO metabolism and/or availability would lead
to alterations in tissue blood flow and oxygenation, and thereby
improve tolerance and performance in a hypoxic environment.
Such a finding could have implications for the treatment of
hypoxaemic critically ill patient.
Hypothesis. The administration of a dietary supplement rich in
nitrate will improve oxygen efficiency during exercise (the
oxygen consumption (VO2) to work rate (WR) relationship at
steady-state) by augmenting tissue blood flow and oxygenationin the microcirculation. Furthermore, nitrate supplementation
will lead to measurable increases in NO bioactivity throughout
the body.2. Materials and methods
The Xtreme Alps expedition was a double-blind randomised
controlled trial investigating the effects of dietary nitrate
supplementation on acclimatisation to hypobaric hypoxia at
high altitude in healthy human volunteers. Investigators from
the University College London (UCL) Centre for Altitude, Space
and Extreme Environment (CASE) Medicine conducted the
study, in collaboration with Warwick University. Ethical
committee approvalwas obtained fromUCL and the University
of Turin.
The primary outcome measurements were a change in
oxygen efficiency during exercise at high altitude between
the participants allocated to receive nitrate supplementation
and those receiving a placebo. Secondary outcome measures
included the presence of symptoms of acute mountain
sickness(AMS),basic physiological measurements (including
oxygen saturation, blood pressure, heart rate and respiratory
rate), exercise capacity, microcirculatory blood flow, forearm
blood flow, cardiac output, skeletal muscle oxygenation,
plasma nitrate and related metabolites, basic lung function
and exhaled NO levels.2.1. Sample size and power calculation
Our primary outcome variable was the change in oxygen
efficiency during exercise, which we have previously deter-
mined to be 22.3 (±1.8) % at sea level in a similarly selected
group of healthy volunteers [9]. Others have shown that
beetroot juice has the ability to improve this efficiency at sea
level by 7.1% [15]. Generation of NO via the nitrate–nitrite–
NO reduction pathway is expected to be enhanced under
conditions of reduced oxygen availability. Thus assuming a
greater effect of beetroot juice at altitude compared to sea
level, we calculated that in order to demonstrate a 10%
improvement in oxygen efficiency 14 subjects would be
required in each group, based upon an α level of 0.05
(two-tailed) and β level of 80% (StatMate2, Graphpad
software, San Diego, CA).2.2. Enrolment and screening
Eligible participants were aged ≥18 years and not known
to be pregnant; anyone deemed unfit to perform exercise at
high altitude as previously described [4] was excluded from
the study. Participants were recruited using communications
sent to recipients of electronic mail from UCL CASE Medicine.
These were primarily scientists, medical students and health
care workers with an interest in high altitude medicine. A
formal health-screening questionnaire was completed prior
to acceptance into the study (Appendix A) and reviewed by
the expedition medical officer (MK). Anyone deemed to be at
risk of health problems at high altitude was assessed in
person by the medical officer prior to enrolment.
Fig. 1. Ascent profile during the Xtreme Alps expedition to 4559 m. Due to
impending severe weather conditions, group A remained for only two nights
at 3611 m before further ascent to the Margherita Hut (4559 m), whilst
group B ascended after three nights at this altitude.
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A total of 28 participants were recruited 21 (75%) of
whom were male. Mean age was 28.9 years (21–40), mean
weight 73.3 Kg (±11.6), mean height 1.76 m (±0.08); mean
BMI 23.6 (±2.69); 3.6% smokers; and 75% had previous
exposure to attitude = 3000 m. Subjects were divided into
two groups (A and B) according to their availability, and the
groups ascended to the Margherita Hut one after the other,
with seven days between start of ascent.
2.4. Informed consent
All participants were provided with an information sheet,
after which they had the opportunity to ask and have
questions answered. If the participant was willing to
participate, written informed consent was obtained and a
unique identification number was then assigned.
2.5. Randomisation and blinding
Following enrolment participants were randomly allocated
to one of two groups, intervention or placebo. We used a
custom-designed 2 × 2 randomisation generator (Matlab
routine, courtesy of Dr. F. Rigat), which conforms to the
CONSORT 2010 guidelines (http://www.consort-statement.
org/) and took into account the need for equal numbers of
individuals in both groups whilst maintaining gender distribu-
tion. Both, participants and investigatorswere blinded to group
allocations for the duration of the study, including the analysis
of the primary data sets. During sea-level and high altitude
testing group allocation information was kept in a closed
envelope solely for access in emergencies; this envelope
remained sealed throughout the study.
2.6. Intervention
The intervention was a custom formulated all-natural
beetroot/fruit juice blend (produced and generously provided
by Aurapa GmbH, Bietigheim-Bissingen, Germany), high in
nitrate. The total daily nitrate dose targeted by this interven-
tion was on the same order of magnitude (range 0.10–
0.18 mmol/kg/day) as that shown by others to be effective in
improving exercise performance at sea level [15,16] and
divided into three individual doses for consumption in the
morning, at midday and in the evening. The placebo juice was
not entirely nitrate-free but contained a significantly (N90%)
reduced content, which was achieved by using a beetroot
juice in which nitrate was removed using a proprietary
selective microbial denitrification method. Administration, at
both sea level and high altitude, commenced 72 h prior to
testing and continued throughout the study period. In order
to account for dietary nitrate intake during the study period,
meals were standardised in order to reduce excessive nitrate
content. Also, a sample of each course was collected, blended
and stored at−40 °C for later nitrate content analysis.
2.7. Study setting
The study took place in August 2010 at the Capanna Regina
Margherita (‘Margherita Hut’), on the summit of Monte Rosaat 4559 m above sea level. The hut belongs to the Italian
Alpine Club, and contains within it a research laboratory that
is managed by the University of Turin, Italy.
Baseline measurements were conducted in London at
75 m above sea level: mean barometric pressure 100.5 kPa,
mean ambient temperature 24.1 °C and mean oxygen partial
pressure 19.7 kPa. Participants then flew to Milan (102 m)
and remained there overnight. Ascent began the following
day by road to Alagna (1205 m), by gondola and cable car to
Punta Indren (3250 m), and finally on foot to the Gnifetti Hut
(3611 m). Due to impending severe weather conditions,
group A remained for only two nights at 3611 m before
further ascent to the Margherita Hut (4559 m), whilst group
B ascended after three nights at this altitude. Ascent to the
highest altitude was by foot; subjects remained at this
altitude for the duration of the study before descending
(eight nights for group A, seven for group B) (Fig. 1). In the
laboratory at 4559 m the mean barometric pressure was
78.1 kPa, mean ambient temperature 22.6 °C and mean
partial pressure of oxygen 15.1 kPa.
2.8. Measurements
All participants had the followingmeasurements taken, both
at sea level and at altitude in the Margherita Hut laboratory.
2.9. Nitrate measures
A number of methods were used to measure the
concentrations of nitrate, nitrite and other NO metabolites
in bodily fluids to obtain information about the absorption,
distribution, metabolism and excretion of nitrate, its poten-
tial cross-talk with endogenous NO metabolites and effects
on pulmonary and renal function.
2.9.1. Plasma nitrite/nitrate concentration
Fasted venous blood samples (5 ml) were taken once at
sea level, and on eachmorning during the study at altitude, in
EDTA-containing tubes (BD Vacutainer). This sample was
then immediately centrifuged at 800 ×g for 15 min; 1 ml of
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individual cryovials and frozen at −40 °C.
2.9.2. Lung function and exhaled nitric oxide
An ultrasonic spirometer (Easy-One, NDD Medical Tech-
nologies, MA, USA) was used to measure standard spiromet-
ric variables. Two hand-held spirometric analysis devices
connected to gas phase chemiluminescence analysers (CLD88sp
with Spiroware software, EcoMedics, Duernten, Switzerland)
were used in parallel for breath-to-breath analysis of inhaled
and exhaled NO, using individual disposable Spirettes and
bacterial filters. Two Denox 88 units (EcoMedics, Duernten,
Switzerland) were used to provide NO-free air and enable
expiratory flow control according to current American
Thoracic Society/European Respiratory Society recommenda-
tions for exhaled NO measurements [17]. Both chemilumi-
nescence analysers were equipped with additional stainless-
steel bulkhead fittings to supply their ozone generators with
pure oxygen from a cylinder (instead of room air) for optimal
performance at the reduced pressure at high altitude; devices
were calibrated dailywith NO (4.00 ppm) and nitrogen (100%
N2 as zero gas) at sea-level as well as at altitude.
2.9.3. Oral nitrate reduction test
The efficiency of nitrate reduction that takes place with
commensal oral bacterial flora was assessed by analysis of
the conversion of 15N-labelled sodium nitrate into 15N-nitrite
[18]. After rinsing the mouth with mineral water, 20 ml
of the 15N-labelled nitrate solution was held in the par-
ticipant's mouth for exactly 3 min before collecting the
entire volume. Two 1 ml sampleswere aliquoted into a cryovial
and stored at −40 °C. The test was performed before the
mid-day meal, and not directly after ingestion of the beetroot
supplement.
2.9.4. Saliva collection
Samples of unstimulated saliva were collected for nitrite
and nitrate measurements using dedicated collection devices
(Salimetrics Oral Swabs; State College, PA, USA). Swabs were
placed under the tongue for 2 min, and then placed into
dedicated collection tubes prior to centrifuging at 3000 rpm for
15 min. Two 0.5 ml aliquots of saliva were stored in cryovials
at−40 °C before analysis in the UK. Samples were taken just
prior to the mid-day meal, and subjects were not allowed to
have their teeth brushed shortly before collection, recently
consumed their beetroot supplement, or have had recent acute
hypoxic exposure.
2.9.5. Exhaled breath condensate collection
Exhaled breath condensate was collected in a non-invasive
manner by breathing for 15 min through a mouthpiece
connected to a sampling tube contained within an insulated
pre-cooled aluminium sleeve (RTube®, Respiratory Research,
Inc., Charlottesville, VA, USA). Two 1 ml aliquots of exhaled
breath condensate were frozen immediately after collection
and kept at−40 °C for later determination of oxidative stress
markers and cytokine measurements.
2.9.6. Urine collection
Twenty-four hour urine collections were obtained at sea
level and twice at high altitude for calculation of creatinineclearance, nitrite and nitrate clearances and excretion. The
collection began following early morning voiding, and
precisely 24 h after starting the urine collection the partic-
ipant urinated for the final time. Urine was collected in 5 litre
containers, total volume was determined, after mixing if
more than one container was used, and a 15 ml aliquot was
frozen at−40 °C. The first sample collection commenced on
expedition day five and the second on day eight.
2.10. Metabolic measures
2.10.1. Resting metabolic rate (RMR)
Participants rested in a comfortable, awake state for
45 min whilst their RMR was measured via indirect calorim-
etry using a validated breath analysis system (Metamax 3b,
Cortex, Leipzig, Germany). Measurements of oxygen uptake
and carbon dioxide production during the final 15 min of rest
were used to determine RMR.
2.10.2. Maximum exercise capacity
A maximal incremental ramp cardiopulmonary exercise
test (CPET) was performed on a fully calibrated electromag-
netically braked cycle ergometer (Lode Corival, Lode, Gro-
ningen, Netherlands) using a breath-by-breath gas-exchange
analysis system (Metamax 3b, Cortex, Leipzig, Germany). The
guidelines for this protocol had been established from the
CXE 2007 expedition [4] based on the American Thoracic
Society/American College of Chest Physicians guidelines for
clinical exercise testing [19]. Peak oxygen uptake (VO2 peak)
during the test was selected as the specific measure of
exercise performance. This is a common and well validated
assessment of fitness used by both exercise physiologists and
clinicians [20]. A full calibration of the equipment was
performed prior to each test.
2.10.3. Exercise efﬁciency and economy
Immediately prior to the maximal incremental ramp test,
both exercise efficiency and economy were assessed using a
constant work rate cycling test. Participants cycled at three
steady state work rates (20, 40 and 60 W) below their lactate
threshold for 10 min each. The work rates were selected based
upon our previous work at altitude when lactate values were
measured to ensure that they were below the anaerobic
threshold [4]. Exercise economy was defined as the relationship
between oxygen consumption and work rate during exercise
(ml/min/W), and exercise efficiency was expressed as delta
efficiency [4]. Samples of venous blood (5 ml) were taken via an
18G intravenous cannula after 2 min of rest prior to commenc-
ing exercise, after minute 8 of each of the three stages of work,
and 1 min after cessation of exercise. Two blood samples of 1 ml
were aliquoted into cryovials and placed at−40 °C.
2.11. Cardiovascular measures
2.11.1. Cardiac output
At baseline and throughout both above exercise tests,
cardiac output was measured using a non-invasive biore-
actance system (NICOM; Cheetah Medical, Inc., Vancouver,
WA, USA). Bioreactance is based on the principle that electrical
impedance across the thorax, resistance to the flow of a high
frequency current, is proportional to the amount of blood in the
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related to the rate of change of fluid in the chest over time,
which is the blood flow. Because the changes in impedance
take place during ventricular contraction, stroke volume can be
calculated.
2.11.2. Echocardiography
All study subjects underwent a resting echocardiogram
(MicroMaxx, SonoSite, UK) at sea level for the assessment of
tricuspid regurgitation (TR). At sea level, participants with
known TR underwent estimation of systolic pulmonary artery
pressure (SPAP) using a standard echocardiographic technique
[21–23]. Volunteers laid in the left lateral position and an apical
four-chamber view of the heart was obtained. Doppler ultra-
sound was used to measure the maximum pressure gradient
across the tricuspid valve during systole (ΔP), and SPAP was
calculated using an estimated right atrial pressure (RAP) of
5 mm Hg (SPAP = ΔP + RAP). At each time point, SPAP was
calculated from the mean of three to five measurements.
Images were stored digitally for subsequent analysis.
Measurements were obtained both at sea level, and
altitude. At sea level, participants had echocardiograms after
breathing room air (21% oxygen), and following exposure to
30 min of hypoxic air (12%). The hypoxic air was delivered
using a hypoxic generator (McKinley Altitude Simulator,
Higher Peak Performance) via tight fitting facemasks and 12%
was selected to emulate the conditions at 4559 m. At altitude
this process was reversed: having undergone a resting
echocardiogram in room air (12% oxygen), a second echo-
cardiogram was conducted after 30 minute inhalation of 35%
oxygen to simulate the sea level partial pressure of oxygen.
2.11.3. Forearm blood ﬂow
Forearm blood flow in the dominant arm was assessed
non-invasively using strain gauge venous occlusion plethys-
mography (EC6 with rapid cuff inflator EC20/AG101 and
NIVP3 software; D. E. Hokanson, Inc., Bellevue, WA, USA). A
mercury-in-silastic strain gauge of the appropriate size was
placed around the maximal circumference of the forearm as
the subject rested with their arm elevated to the level of the
right atrium. Having occluded the hand circulation using a
wrist cuff inflated to 250 mm Hg, a blood pressure cuff
placed around the upper arm was inflated to 50 mm Hg, and
resting blood flow measurements were taken and oxygen
saturation levels recorded. After cuff deflation and 1 min of
rest, a standard forearm exercise protocol was performed
followed by immediate re-inflation of both cuffs and
subsequent recording of circumference changes. The exercise
protocol following basal arterial inflow measurements com-
prised of a series of repeated handgrips of a foam ball for
2 min at a frequency of 0.5 Hz. Measurements at sea level
were taken whilst breathing room air (21% oxygen), and
following 45 min of breathing a hypoxic gas mixture (12%).
As with the echocardiogram, this process was reversed at
altitude with 35% oxygen. Total forearm volume was
determined for each individual by water displacement to
allow for later normalisation of responses.
2.11.4. Skeletal muscle oxygen saturation
A vascular occlusion test was performed with skeletal
muscle oxygen saturation (StO2)measured using near-infraredspectroscopy (NIRS) (InSpectra Model 325; Hutchinson Tech-
nology, Hutchinson, MN, USA) in the thenar eminence of the
dominant hand. Subjects sat with their arm supported at the
level of the right atrium, a probe was applied to their thenar
eminence and after a three minute period of stabilisation, a
blood pressure cuff was rapidly inflated on the upper arm to
250 mm Hg. After 3 min of arterial occlusion the cuff was
rapidly deflated and StO2 measurements continued for 5 min.
Analysis of the rate of muscle desaturation and resaturation
provides insights into skeletal muscle oxygen consumption
and microvascular reactivity. Measurements at sea level were
taken whilst breathing room air (21% oxygen), and following
35 min of breathing a hypoxic gas mixture (12%). As with the
echocardiogram and venous plethysmography, this process
was reversed at altitude by using 35% oxygen.2.11.5. Sublingual microcirculation
Whilst at rest and in the supine position, participant's
sublingual microcirculation was imaged by sidestream dark
field (SDF) imaging using a non-invasive hand held video
microscope placed under their tongue (MicroVision Medical,
Amsterdam, Netherlands), as previously described [24]. Four
20-second films were recorded from each subject and
assessed using the AVA microcirculatory analysis software
(MicroVision Medical, Amsterdam, Netherlands).2.12. Organ function measures
2.12.1. Hepatic metabolism
Changes in global liver function and splanchnic circulation
were assessed using a LiMON device (Pulsion Medical
Systems, Munich, Germany). This non-invasive device mea-
sures the elimination of the diagnostic drug indocyanine
green (ICG). As the subject sat at rest, a small dose of ICG
(0.25 mg/kg) was injected intravenously and its blood
concentration observed over a 15 minute period by transcu-
taneous pulse densitometry using a probe placed upon the
index finger of the non-cannulated hand. ICG elimination
kinetics are a function of hepatic biotransformation and
splanchnic circulatory blood flow.2.12.2. Renal function
At sea level and twice at high altitude early morning urine
was collected and analysed on site for albumin:creatinine
ratio (DCA Vantage Analyzer, Siemens) as a measure of renal
protein leak.2.12.3. Cerebral blood ﬂow and oxygenation
Whilst at rest and having been positioned supine for
10 min subjects had their cerebral blood flow and cerebral
tissue oxygen saturations (SctO2) measured. The Fore-sight
Absolute Cerebral Oximeter (Casmed, Branford, CT, USA) was
used to measure the saturation of cerebral tissue using NIRS
probes placed 1.5 cm above the eyebrow overlying the right
hemisphere. Cerebral blood flow in the middle cerebral
artery was measured via the right temporal window using
Transcranial Doppler (MicroMaxx, Sonosite, Bothell, WA,
USA) and a 5-1 MHz transducer.
Table 1
The 2 × 2 factorial analysis of the interaction of intervention and altitude.
Sea level Altitude
Intervention a b
Placebo c d
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Assessment of muscle wasting was undertaken whilst at
rest with ultrasound (Micromaxx, Sonosite, UK) using a
5 MHz linear array transducer (model HFL38). Limb mea-
surements, in accordance with the protocol described by
Campbell and Reid [25,26], were made on the non-dominant
side of the subject to identify a mid-point of the limb (bicep,
forearm and thigh) with the subject in the supine position.
Permanent marker was used to ensure that measurements
were made on the same site every time. Three measurements
were made using the built-in electronic calliper on a frozen
real-time cross-sectional image and averaged. Measurements
were taken of the biceps, forearm and thigh muscles. Subjects
were measured at sea level and on two occasions at altitude,
three days apart.
2.13. Subjective symptom measures
2.13.1. Daily diary
Participants were required to complete a diary of
physiological measures and symptoms. Completion of the
diary was performed on each morning of the expedition prior
to any intake of food (including intervention or placebo
juice) or caffeine. The diary included a validated symptom
score for AMS; the Lake Louise score [27,28]. Peripheral
oxygen saturation (SpO2), heart rate, blood pressure and
respiratory rate were recorded after 5 min of rest. SpO2, heart
rate and respiratory rate were also recorded again after 2 min
of controlled step exercise. Finally, anymedication prescribed
or otherwise taken was recorded in the diary along with
alcohol intake. The daily diary entry sheet is shown in
Appendix B.
2.14. Additional studies
In addition to the studies mentioned above, a number of
subsidiary studies were performed on a separate cohort of
subjects not involved in the main randomised controlled
trial. Whole body oxygen extraction during exercise at
altitude was investigated in five subjects, and the time-
course of hypoxic pulmonary hypertension at high altitude
was examined in four subjects.
2.15. Sample transport
All samples from the above experiments were transported
back to the UK for analysis, with the frozen specimens
transported on dry ice. Electronic thermistors measured
transportation temperatures throughout.
2.16. Risk management
CASE Medicine has extensive experience with performing
research in remote high altitude environments. Initially, the
expedition medical officer screened all potential study partic-
ipants. Written ‘Life Threatening Illness’ and ‘Evacuation’
protocolswere produced and communicated to all participants.
At all times a medical doctor was present in the research
laboratory, as was a full medical kit, resuscitation equipment,
and supplementary oxygen.2.17. Analysis plan
In a multi-staged approach to analysis we intend to follow
the plan outlined below:
• Subjects, investigators collecting data and those analysing
data were all blinded to which group subjects were in
(intervention/placebo)
• Entry of individual physiological components into a
comprehensive database
• Unblinding of subject cohort allocation
• Comparison of results between intervention and placebo
cohorts
• Intention-to-treat analysis of the primary outcome vari-
able: intervention vs. control. Additional analyses of second
outcome variables and by intervention received will then
be conducted.
• Investigation of the effect of altitude combined with
intervention through 2 × 2 factorial-type analysis of four
cohorts (Table 1).
All data will be tested for normality of distribution and
transformed/analysed accordingly. Primary outcome measure-
ments of the cohorts outlined in Table 1 will be compared with
simple t-testswhile secondary outcome (hypothesis-generating)
variables will be analysed as deemed most appropriate once the
entire data setwill be available.Most of the variableswill be data
on a continuous scale rather than yes/no answers, and may best
be analysed by comparing differences rather than absolute
values. We will also be interested in exploring the relationship
between different sets of variables using multiple linear
regression analysis, but realise that the sample size may be
insufficient to make adjustments for gender, anthropometric
differences, etc.3. Discussion
This translational study, exploring the efficacy of a dietary
supplementation on human acclimatisation to high altitude
may have implications for hypoxaemic critically ill patients.
The NO pathway offers potential for manipulation in critically
ill patients, and the paradigm of healthy volunteers ascend-
ing to altitude is a valid testing ground for hypotheses.
Results from this study will inform further field studies, more
complex mechanistic investigations in hypobaric chambers
and clinical trials in the critically ill. It also demonstrates the
feasibility of performing complex randomised controlled
studies with multiple physiological measures in a hostile,
remote environment.
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This pragmatic but robust approach to investigating
potential therapeutic agents in a healthy volunteer model of
hypoxaemia will provide data that are difficult to generate
through alternative strategies such as animal models and cell
culture. It is possible to use a hypobaric chamber to create a
hypoxic environment but experiments using this method are
limited by cost, tolerability and the risk of decompression
illness for investigators who need to frequently enter the
chamber. Although effects of nitrate supplementation on
skeletal muscle function have been tested in the acute
hypoxic setting [16], such effects are likely to differ from
those in the more chronic setting, as studied in our field
research. Description of integrative physiological changes in
human subjects will help determine whether or not this
intervention will be a suitable candidate for clinical trials. A
double-blind randomised controlled approach to testing the
intervention will minimise bias that would otherwise be
introduced if other methodologies had been adopted. Strict
blinding during data analysis will guarantee that the results
will not have been influenced by any pre-conceived ideas
held by investigators. Matching ascent profiles amongst the
participants allows valid inter-individual comparison of re-
sponses to hypoxia, maximising the signal (true physiological
differences) to noise (variations in exposure to environmental
hypoxia) ratio. Rigorous validation and calibration procedures
were followed throughout the study, as per our previously
described field study [4].
High altitude is a hostile environment in which factors
other than hypoxia may determine direction and quality of
the physiological responses observed. These include exertion
during exercise during ascent to altitude, environmental
temperature, dehydration, intercurrent systemic illness and
altitude-related illness. The experiments in this study were
therefore conducted in a laboratory with environmental
conditions comparable to those experienced at sea level
(other than its lower barometric pressure) and after more
than 24 h of rest following ascent.
Due to the design of the study, there is a possibility
that baseline differences between individuals in the in-
tervention and placebo groups could influence outcome
measures. The reason for this is that it was not possible
to perform absolute baseline tests on the group prior to
randomisation. We were unable to recruit a full partici-
pant cohort that was willing to undergo testing at sea level
before and after randomisation. There is also potential bias
from volunteer self-selection, given that those inclined
to climb to high altitude may not be representative of
the average population; factors include age and level of
physical fitness. Additionally, there were cost implica-
tions to participating in the expedition and this may have
deterred some volunteers from participating. The small
group size also limits any subgroup analysis and risks the
possibility of a type II error for some of the measurements
taken.
4. Conclusion
This innovative study into the efficacy of oral nitrate
supplementation in augmenting human adaptation to hypobarichypoxaemia may have direct application to clinical medi-
cine. It is hoped that it will ultimately improve and enhance
our understanding of hypoxaemic patients and provide new
therapeutic avenues for potential interventions to improve
survival in the critical care environment.
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Volunteer name:
Altitude/travel history
Have you travelled above 3000 m (9000 ft) before?
What is the maximum altitude you have reached previously?
For mountaineers, number of ascents above each altitude listed and oxygen use
5000 m 6000 m 7000 m 8000 m
Have you previously suffered from Acute Mountain Sickness?
If yes, please describe details (continue on another sheet if necessary)
Did you have to descend/abandon a trip to high altitude?
Have you previously suffered from HAPE (High altitude pulmonary oedema)?
If yes, please describe date, and details
Have you previously suffered from HACE (High altitude cerebral oedema)?
If yes, please describe date, altitude suffered and details
Have you ever suffered from frostbite, frostnip or cold injury?
If yes, please describe details
Have you travelled abroad in the last year? If so where?
Have you ever suffered from medical problems abroad?
(If yes give details)
Volunteer name:
Medication history
Are you taking any medication on a regular basis including the oral contraceptive
(Please list)
Have you ever been on any long term medication including psychiatric drugs? Pl
Are you allergic to any medications?
Are you taking any herbal remedies or alternative medicines?
(Please list)
In the last year have you used any recreational drugs? If so what, and how often
Are you taking any vitamin supplements or food supplements?
(Please list)
Do you smoke? (This includes “social smoking”)
How many manufactured cigarettes per day/week? For how many years?
How many cigars per day/week? For how many years?
How much pipe tobacco per week? For how many years?
How much hand-rolling tobacco per week? For how many years?
Do you drink alcohol?
On average, how much do you drink a week? (Give answer in pints/glasses/spi
Do you drink coffee regularly
Approximately how many cups a day?
Volunteer name:
Past medical history
Have you visited your GP or hospital in the last 12 months for anything apart from a c
and continue on another sheet if required
In the past year have you attended hospital or had an operation?
Are you currently on the waiting list to see a hospital doctor/specialist for any
Do you suffer from/have you ever had any form of heart disease?
Do you suffer from/have you ever had any form of kidney disease?
Do you suffer from/have you ever had any form of liver disease?
Do you suffer from/have you ever had high blood pressure/hypertension?
Do you suffer from/have you ever had any lung disease?
Do you suffer from/have you ever had asthma?
Do you suffer from/have you ever had epilepsy/blackouts/fits/funny turns
Have you ever suffered from a psychiatric or psychological condition, including d
Do you suffer from diabetes?
Do you suffer from any allergies?
If the answer to any of the above questions is yes, please give details belowthe statistical advice, and Drs. Arnold Leckstrom and Heather
Riley for the assistance with sea level measurements and
preliminary data analyses.l subjects
Y/N
ft/m
Y/N
Y/N
Y/N
Y/N
Y/N
Y/N
Y/N
pill? Y/N
ease give details. Y/N
Y/N
Y/N
do you use the drug? Y/N
Y/N
Y/N
rit measures)
Y/N
heck-up? Please give details Y/N
reason? Please give details.
Y/N
Y/N
Y/N
Y/N
Y/N
Y/N
Y/N
Y/N
epression Y/N
Y/N
Y/N
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